SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

019770106

(CUSIP Number)

Michael LaGatta

TPG Global, LLC

301 Commerce Street, Suite 3300

Fort Worth, TX 76102

(817) 871-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 6, 2020

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 8 Pages)

____________

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

This Amendment No. 3 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on October 25, 2018, as amended and supplemented by Amendment No. 1 filed on May 15, 2019 and Amendment No. 2 filed on July 10, 2020 (as so amended, the “Original Schedule 13D” and, as amended and supplemented by this Amendment, the “Schedule 13D”), with respect to the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

Item 2. Identity and Background.

This Amendment amends and restates the second paragraph of Item 2 of the Original Schedule 13D in its entirety as set forth below:

“Group Advisors is the sole member of TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of each of (i) TPG GenPar VII Advisors, LLC, a Delaware limited liability company and (ii) The Rise Fund GenPar Advisors, LLC, a Delaware limited liability company. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., a Delaware limited partnership, which is the general partner of TPG Carthage Holdings, L.P., a Delaware limited partnership, which directly holds 12,477,536 shares of Common Stock. The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., a Delaware limited partnership, which it the general partner of The Rise Fund Carthage, L.P., a Delaware limited partnership (together with TPG Carthage Holdings, L.P., the “TPG Funds”), which directly holds 6,238,770 shares of Common Stock.”

Item 4. Purpose of Transaction.

This Amendment amends and supplements Item 4 of the Original Schedule 13D by inserting the following after the paragraph titled “June 2020 Sales”:

“August 2020 Distribution in Kind

Effective August 6, 2020, the TPG Funds distributed, in accordance with their limited partnership agreements and pursuant to a Rule 10b5-1 plan, an aggregate of 1,000,000 shares of Common Stock to their limited partners, some of which made further pro rata distributions of the shares of Common Stock to their limited partners (the “August 2020 Distribution”), with some of the foregoing that are affiliated with Group Advisors having established Rule 10b5-1 trading plans for the sale of the shares of Common Stock received in the August 2020 Distribution (those whose sales are reported herein, the “TPG Sales Vehicles”).

In connection with the August 2020 Distribution and pursuant to Rule 10b5-1 trading plans, the TPG Sales Vehicles sold (i) an aggregate of 4,600 shares of Common Stock on August 6, 2020 in open market sales at a weighted average price per share of $38.2158 in multiple transactions at prices ranging from $37.92 to $38.53, inclusive; (ii) an aggregate of 19,554 shares of Common Stock on August 6, 2020 in open market sales at a weighted average price per share of $37.3326 in multiple transactions at prices ranging from $36.90 to $37.76, inclusive; (iii) an aggregate of 5,605 shares of Common Stock on August 7, 2020 in open market sales at a weighted average price per share of $37.0215 in multiple transactions at prices ranging from $36.48 to $37.47, inclusive; and (iv) an aggregate of 7,686 shares of Common Stock on August 7, 2020 in open market sales at a weighted average price per share of $37.6959 in multiple transactions at prices ranging from $37.51 to $37.99, inclusive. The Reporting Persons undertake to provide to the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range of each of the sales above that involved multiple transactions.”

Item 5. Interest in Securities of the Issuer.

This Amendment amends and restates the second paragraph of Item 5 of the Original Schedule 13D in its entirety as set forth below:

“(a)-(b) The following sentence is based on 139,291,518 shares of Common Stock outstanding as of August 3, 2020, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on August 5, 2020. Pursuant to Rule 13d-3 under the Act, the Reporting Persons may be deemed to beneficially own 18,716,306 shares of Common Stock, which constitutes approximately 13.4% of the outstanding shares of Common Stock.”

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 10, 2020

(1) Gerald Neugebauer is signing on behalf of Mr. Bonderman pursuant to an authorization and designation letter dated February 26, 2020, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Bonderman on March 6, 2020 (SEC File No. 001-38156). 

(2) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated February 26, 2020, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on March 6, 2020 (SEC File No. 001-38156).

INDEX TO EXHIBITS